<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Pathogenesis of allergic rhinitis (rhinosinusitis)</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Pathogenesis of allergic rhinitis (rhinosinusitis)</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Pathogenesis of allergic rhinitis (rhinosinusitis)</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard D deShazo, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Stephen F Kemp, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jonathan Corren, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Anna M Feldweg, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 09, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Allergic rhinitis is associated with a symptom complex characterized by paroxysms of sneezing, rhinorrhea, nasal obstruction, and itching of the eyes, nose, and palate. It is also frequently associated with postnasal drip, cough, irritability, and fatigue [<a href="#rid1">1-4</a>].</p><p>The pathogenesis of allergic rhinitis is presented in this topic review. The clinical manifestations, diagnosis, and treatment of this condition are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7528.html" rel="external">"Chronic rhinosinusitis: Clinical manifestations, pathophysiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7525.html" rel="external">"Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/7526.html" rel="external">"Pharmacotherapy of allergic rhinitis"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">MECHANISMS OF UPPER AIRWAY ALLERGIC REACTIONS</span><span class="headingEndMark"> — </span>Upon exposure to an allergen, atopic individuals respond by producing allergen-specific immunoglobulin E (IgE). These IgE antibodies bind to IgE receptors on mast cells in the respiratory mucosa and to basophils in the peripheral blood. When the same allergen is subsequently inhaled, the IgE antibodies are bridged on the cell surface by allergen, resulting in activation of the cell. Mast cells in the nasal tissues release preformed and granule-associated chemical mediators, which cause the symptoms of allergic rhinitis.</p><p>Models of nasal allergen challenge in patients with allergic rhinitis have provided information about the pathogenesis of allergic rhinitis [<a href="#rid5">5,6</a>]. In this model study system, individuals known to have allergic rhinitis on exposure to a particular allergen are exposed to incremental doses of that allergen placed in the nose. The subsequent reaction is then monitored over time with nasal biopsies or washes. This allows direct quantitation of cell types by stains and surface markers, assessment of message for transcription, or direct measurement of cellular cytokines and other inflammatory mediators [<a href="#rid7">7</a>]. Rhinomanometry, the measurement of nasal airway resistance, permits measurement of both resistance and airflow following allergen provocative challenge [<a href="#rid8">8</a>]. (See  <a class="medical medical_review" href="/z/d/html/7529.html" rel="external">"Occupational rhinitis", section on 'Rhinomanometry techniques'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Immunogenetics</span><span class="headingEndMark"> — </span>The expression of allergic diseases of the upper airways reflects an autosomal dominant pattern of inheritance with incomplete penetrance. This inheritance pattern is manifested as a propensity to respond to inhalant allergen exposure by producing high levels of allergen-specific IgE. The IgE response appears to be controlled by immune response genes located within the major histocompatibility complex (MHC) on chromosome 6. (See  <a class="medical medical_review" href="/z/d/html/3969.html" rel="external">"Major histocompatibility complex (MHC) structure and function"</a>.)</p><p>The immunologic mechanisms of atopy have been studied in murine models and in humans. These mechanisms involve the expression of a repertoire of responses associated with T helper type 2 (Th2) lymphocytes. There are probably multiple genetic and environmental influences that lead to overexpression of Th2 T cell responses relative to T helper type 1 (Th1) cell responses (<a class="graphic graphic_figure graphicRef53928" href="/z/d/graphic/53928.html" rel="external">figure 1</a>). (See  <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p class="headingAnchor" id="H4"><span class="h2">IgE production</span><span class="headingEndMark"> — </span>Sensitization to allergen is necessary to elicit an immunoglobulin E (IgE) response (<a class="graphic graphic_figure graphicRef75380" href="/z/d/graphic/75380.html" rel="external">figure 2</a>). After inhalation, the allergen must first be internalized by antigen-presenting cells (APCs), which include macrophages, immature dendritic cells, B lymphocytes, and epithelial cells [<a href="#rid9">9</a>]. After allergen processing, peptide fragments of the allergen are exteriorized and presented with class II MHC molecules of host APCs to CD4+ T lymphocytes. (See  <a class="medical medical_review" href="/z/d/html/3980.html" rel="external">"The adaptive cellular immune response: T cells and cytokines"</a>.)</p><p>Allergenic proteases activate and damage nasal epithelial cells, which then secrete interleukin (IL)-25, IL-33, thymic stromal lymphopoietin (TSLP), and other cytokines that impact Th2 lymphocytes and group 2 innate lymphoid cells (ILC2s) directly or indirectly via APCs located within and underneath the nasal epithelium. Activated T lymphocytes proliferate into effector memory Th2 cells that secrete IL-4, IL-5, IL-9, and IL-13 [<a href="#rid9">9</a>].</p><p>B lymphocytes require two signals for isotype switching to IgE (see  <a class="medical medical_review" href="/z/d/html/3977.html" rel="external">"Immunoglobulin genetics"</a> and  <a class="medical medical_review" href="/z/d/html/13933.html" rel="external">"Normal B and T lymphocyte development"</a>). In the first signal, IL-4 or IL-13 stimulate transcription at the Ce locus, the site of exons that encode the constant region of the IgE heavy chain [<a href="#rid10">10</a>] (see  <a class="medical medical_review" href="/z/d/html/5542.html" rel="external">"The biology of IgE"</a>). Interaction of CD40 on the B cell membrane with CD40 ligand (CD40L) on the surface of T lymphocytes provides the second signal that activates genetic recombination in the functional IgE heavy chain [<a href="#rid11">11</a>]. IL-4 and IL-13 also upregulate vascular cell-adhesion molecule-1 (VCAM-1) on endothelial cells, promoting adhesion of inflammatory cell populations, and they facilitate their migration into areas of allergic inflammation. (See  <a class="medical medical_review" href="/z/d/html/3983.html" rel="external">"Leukocyte-endothelial adhesion in the pathogenesis of inflammation"</a>.)</p><p>In situ hybridization and/or antibody studies have demonstrated increased numbers of cells with messenger RNA (mRNA) for and/or expression of IL-3, IL-4, IL-5, IL-13, eotaxin, and granulocyte macrophage colony-stimulating factor (GM-CSF) within the nasal mucosa after allergen provocation (<a class="graphic graphic_picture graphicRef77315" href="/z/d/graphic/77315.html" rel="external">picture 1</a>) [<a href="#rid5">5,7</a>]. Interferon-gamma (IFN-gamma), a Th1 cytokine that inhibits B lymphocyte activation and IgE synthesis is absent. Interleukin-12 (IL-12) and interleukin-18 (IL-18), major inducers of IFN-gamma, are also absent.</p><p>Thus, atopy appears to be the result of a predisposition toward Th2 responses, which results in the formation of large quantities of allergen-specific IgE [<a href="#rid5">5</a>].</p><p class="headingAnchor" id="H5"><span class="h2">Mast cell activation</span><span class="headingEndMark"> — </span>After IgE antibodies specific for a certain allergen are synthesized and secreted, they bind to high-affinity receptors on mast cells (and basophils). When allergen is inhaled into the nose, it cross-links these allergen-specific cell-bound IgE antibodies on the mast cell surface in a calcium-dependent process, resulting in rapid degranulation and mediator release. The mediators stimulate blood vessels, nerves, and glands to cause the clinical manifestations of allergic rhinitis and feed back to other elements of the immune system to perpetuate the process.</p><p>The superficial nasal epithelium in patients with allergic rhinitis has 50-fold more basophilic cells (mast cells and basophils) per specimen than does epithelium from nonallergic subjects. Increased concentrations of mast cells are found near postcapillary venules, where they increase vascular permeability; near sensory nerves, where they initiate the sneeze reflex; and near glands, where they facilitate secretion. Nasal mast cells are predominately located in the nasal lamina propria as connective tissue mast cells, although 15 percent are epithelial and called mucosal mast cells. Mucosal mast cells express tryptase without chymase and proliferate in allergic rhinitis under the influence of Th2 cytokines. (See  <a class="medical medical_review" href="/z/d/html/3979.html" rel="external">"Mast cells: Development, identification, and physiologic roles"</a>.)</p><p>Mast cell mediators are either preformed, associated with granules, formed during degranulation, or generated after transcription [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/z/d/html/3972.html" rel="external">"Mast cell-derived mediators"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Histamine</span><span class="headingEndMark"> — </span>Histamine is the most important preformed mediator in allergic rhinitis. Histamine reproduces <strong>all</strong> of the acute symptoms of allergic rhinitis when sprayed into the noses of normal volunteers. Histamine causes mucus secretion, vasodilatation leading to nasal congestion, increased vascular permeability leading to tissue edema, and sneezing through stimulation of sensory nerve fibers.</p><p class="headingAnchor" id="H7"><span class="h3">Prostaglandins and leukotrienes</span><span class="headingEndMark"> — </span>The cross-linking of IgE antibody on mast cells activates phospholipase A2 and releases arachidonic acid from the A2 position of cell membrane phospholipids. Mast cells then metabolize arachidonic acid either via the cyclooxygenase pathway to form prostaglandin and thromboxane mediators or via the lipoxygenase pathway to form leukotrienes. Prostaglandin D<sub>2</sub> (PGD<sub>2</sub>), as well as the sulfidopeptide leukotrienes LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>, are formed during degranulation. PGD<sub>2</sub> is synthesized by mast cells but not basophils and appears to be more potent than histamine in causing nasal congestion. LTB<sub>4</sub> is the most potent chemotactic factor described in humans [<a href="#rid13">13</a>].  </p><p class="headingAnchor" id="H8"><span class="h3">Other mediators</span><span class="headingEndMark"> — </span>Platelet-activating factor (PAF) and bradykinin (generated by the action of tryptase) are also formed during degranulation. PAF is a potent chemotactic factor, and the bradykinins are vasoactive.</p><p class="headingAnchor" id="H9"><span class="h2">Cellular infiltration</span><span class="headingEndMark"> — </span>Once allergic reactions begin, mast cells amplify such reactions by releasing not only vasoactive agents but also cytokines, including GM-CSF, tumor necrosis factor-alpha (TNF-alpha), transforming growth factor-beta (TGF-beta), IL-1 to IL-6, and IL-13 [<a href="#rid14">14-16</a>].</p><p>Tissue eosinophilia is characteristic of allergic rhinitis [<a href="#rid17">17</a>]. It appears that mast cell-derived cytokines promote further IgE production, mast cell and eosinophil growth, chemotaxis, and survival. As an example, IL-5, TNF-alpha, and IL-1 promote eosinophil movement by increasing the expression of adhesion receptors on endothelium. In turn, eosinophils secrete a plethora of cytokines including IL-3, IL-4, IL-5, IL-10, and GM-CSF, which favor, among others, Th2 cell proliferation and mast cell growth. Eosinophils also serve an autocrine function in these reactions by producing the cytokines IL-3, IL-5, and GM-CSF, which are important in hematopoiesis, differentiation, and survival of eosinophils themselves.</p><p>Eosinophils release oxygen radicals and proteins, including eosinophil major basic protein, eosinophil cationic protein, and eosinophil peroxidases. These have been shown to be associated with nasal epithelial injury and desquamation, subepithelial fibrosis, and hyper-responsiveness [<a href="#rid7">7,18</a>]. As a result of mast cell and eosinophil activation in the allergic response, the following events occur in succession:</p><p class="bulletIndent1"><span class="glyph">●</span>Vascular endothelial cell expression of adhesion molecules</p><p class="bulletIndent1"><span class="glyph">●</span>Adhesion of leukocytes to vascular endothelium</p><p class="bulletIndent1"><span class="glyph">●</span>Transendothelial migration</p><p></p><p>Chemotaxis and increased survival of eosinophils occur within areas of allergic inflammation. In addition to the families of adhesion molecules, chemokine molecules that affect the expression and function of adhesion molecules on endothelium and leukocytes are also expressed in these reactions. Increased numbers of cells positive for chemokines, such as RANTES (<strong>r</strong>egulated on <strong>a</strong>ctivation, <strong>n</strong>ormal <strong>T</strong> cell <strong>e</strong>xpressed and <strong>s</strong>ecreted), eotaxins, monocyte chemotactic protein-3 (MCP-3), and MCP-4 are present in the mucosa after allergen challenge [<a href="#rid5">5,19</a>]. These chemokines further enhance the recruitment and activation of inflammatory cells possessing their cell surface receptors in allergic reactions [<a href="#rid7">7</a>]. Nitric oxide (NO), a vasodilator, is also produced in the nasal mucosa of patients with allergic rhinitis and may play a role in the production of nasal obstruction [<a href="#rid20">20</a>]. NO synthetase is expressed by mast cells, neutrophils, and endothelial cells, among others.</p><p class="headingAnchor" id="H10"><span class="h1">IMMEDIATE AND LATE NASAL REACTIONS</span><span class="headingEndMark"> — </span>Exposing the nasal mucosa to ragweed in ragweed-sensitive subjects (nasal challenge) provokes the immediate onset of sneezing and nasal itching associated with significantly increased concentrations of inflammatory mediators. The time course of histamine concentration, symptoms (sneezing), and increases in nasal airway resistance are closely correlated (<a class="graphic graphic_figure graphicRef65419" href="/z/d/graphic/65419.html" rel="external">figure 3</a>) [<a href="#rid21">21,22</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Immediate</span><span class="headingEndMark"> — </span>Within seconds to minutes of allergen exposure, an immediate allergic response is observed, which peaks in 15 to 30 minutes [<a href="#rid17">17</a>]. Sneezing correlates with the appearance of measurable histamine, the kininogen product tosyl-L-arginine methyl ester (TAME esterase), and prostaglandin D<sub>2</sub> (PGD<sub>2</sub>) in nasal washes. Increased levels of sulfidopeptide leukotrienes C<sub>4</sub> and B<sub>4</sub>, tryptase, kinins, albumin, eosinophil major basic protein, and platelet-activating factor (PAF) are also present in nasal washes after allergen challenges [<a href="#rid9">9,23</a>]. The presence of histamine, tryptase, and PGD<sub>2</sub> indicate the central role of the mast cell in the early response to allergen [<a href="#rid22">22</a>].</p><p>After about 30 minutes, PGD<sub>2</sub> and histamine levels return to baseline, whereas TAME esterase concentrations remain elevated. Biopsy specimens of the nasal mucosa at this time show an increased number of degranulated mast cells.</p><p class="headingAnchor" id="H12"><span class="h2">Late</span><span class="headingEndMark"> — </span>A late-phase nasal allergic reaction develops in approximately 50 percent of patients with seasonal rhinitis, which peaks at 6 to 12 hours after nasal allergen challenge [<a href="#rid17">17</a>]. This secondary inflammatory response is thought to be important in establishing the chronicity of the disorder. During this later phase, symptoms may recur after a second release of mast cell mediators that is coincident with maximum mast cell cytokine production [<a href="#rid22">22</a>].</p><p>The late-phase allergic reaction is associated with elevated levels of the same mediators noted in the immediate reaction, except that PGD<sub>2</sub> is not detected. Thus, basophils appear to be partly responsible for such late-phase reactions, because histamine is generated by both mast cells and basophils, whereas only mast cells can produce PGD<sub>2</sub>. In support of this concept, marked basophil influx into the nasal mucosa has been noted 3 to 11 hours after allergen challenge [<a href="#rid9">9,24</a>]. Large numbers of neutrophils, mononuclear cells, and eosinophils also migrate into the nasal mucosa at this time. Increases in eosinophil cationic protein and other eosinophil products also become detectable in nasal secretions. After allergen challenge, lymphocytes remain the predominant cells in the nasal mucosa. These cells actively transcribe messages for interleukin-3 (IL-3), interleukin-4 (IL-4), interleukin-5 (IL-5), and granulocyte macrophage colony-stimulating factor (GM-CSF) and have increased expression of the interleukin-2 (IL-2) receptor. Interleukin-1 (IL-1) through IL-5 and GM-CSF, among others, have been recovered from nasal washes after allergen challenge.</p><p class="headingAnchor" id="H13"><span class="h1">ALTERATIONS OF NASAL PHYSIOLOGY</span><span class="headingEndMark"> — </span>Under normal conditions, the nose accounts for one-half to two-thirds of the resistance to airflow in the airway. It is lined by pseudostratified epithelium, resting upon a basement membrane that separates it from deeper submucosal layers [<a href="#rid17">17</a>]. The submucosa contains mucous, seromucous, and serous glands. The small arteries, arterioles, and arteriovenous anastomoses determine regional blood flow. Capacitance vessels consisting of veins and cavernous sinusoids determine nasal patency. The cavernous sinusoids lie beneath the capillaries and venules, are most dense in the inferior and middle turbinates, and contain smooth muscle cells controlled by the sympathetic nervous system. Withdrawal of sympathetic tone, or to a lesser degree, cholinergic stimulation, causes this sinusoidal erectile tissue to become engorged. Cholinergic stimulation causes arterial dilation and promotes the passive diffusion of plasma protein into glands and active secretion by mucous gland cells.</p><p>The role of neurotransmitters may be important in the pathogenesis of allergic rhinitis. Novel neurotransmitters, including substance P, a chemical that increases vascular permeability, calcitonin gene-related peptide (CGRP), and vasointestinal peptide, have been detected in nasal secretions after nasal allergen challenge of patients with allergic rhinitis [<a href="#rid25">25</a>]. <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">Capsaicin</a>, which depletes sensory nerves of substance P and CGRP, reduces symptoms induced by nasal allergen challenge [<a href="#rid26">26</a>]. Antidromic stimulation of sensory nerve fibers in the nose can release a variety of neurotransmitters, including substance P. Neurotransmitters also produce changes in regional blood flow and glandular secretion.</p><p class="headingAnchor" id="H14"><span class="h1">INVOLVEMENT OF THE PARANASAL SINUSES</span><span class="headingEndMark"> — </span>There are data indicating that the inflammatory response noted in the mucosa of patients with allergic rhinitis is often present in the paranasal sinuses, as well [<a href="#rid7">7</a>]. There is concomitant epithelial denudation, extracellular matrix deposition, and basement membrane disruption.</p><p class="headingAnchor" id="H3488798906"><span class="h1">UNANSWERED QUESTIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>How do genetic and environmental factors (eg, pollution and infection) promote IgE production?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Why do some antigens stimulate Th2 lymphocytes and become allergens and others do not? (In general, allergens do not stimulate Th1 inducing cytokines by macrophages and dendritic cells as antigens do.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What are the specific roles of Th2 cells and Type 2 innate lymphoid cells (both secrete IL-5 and IL-13) as well as Toll-like receptor ligands from injured cells (some activate mast cells) in allergic inflammation?</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>What are the differences in IL-4 secreting Th2 cells (supporting the allergic diathesis) and CD25+ regulatory T-cells (suppressing the allergic diathesis) among allergic and nonallergic individuals? [<a href="#rid9">9,27</a>]</p><p></p><p class="headingAnchor" id="H15"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient education" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topic (see  <a class="medical medical_patient" href="/z/d/html/370.html" rel="external">"Patient education: Allergic rhinitis (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H16"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span>Atopic individuals respond to allergen exposure by producing allergen-specific immunoglobulin E (IgE). IgE antibodies bind to IgE receptors on mast cells throughout the respiratory mucosa and to basophils in the peripheral blood. When the same allergen is subsequently inhaled, the allergen binds to and cross-links IgE on the mast cell surface, resulting in activation and release of inflammatory mediators. (See <a class="local">'Mechanisms of upper airway allergic reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Nasal mast cells release histamine, prostaglandins, leukotrienes, platelet-activating factor (PAF), and bradykinin, among other mediators. These result in the signs and symptoms of allergic rhinitis. Tissue eosinophilia is also a feature of allergic rhinitis, and eosinophil-derived mediators are associated with nasal epithelial injury and desquamation, subepithelial fibrosis, and hyper-responsiveness. (See <a class="local">'Mast cell activation'</a> above and <a class="local">'Cellular infiltration'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The allergic nasal response consists of an immediate phase, which peaks at 15 to 30 minutes after allergen exposure and corresponds to mast cell degranulation and mediator release, and a late phase, which peaks at 6 to 12 hours after exposure and corresponds to infiltration of the nasal tissues by eosinophils, basophils, and other inflammatory cells. (See <a class="local">'Immediate and late nasal reactions'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients with allergic rhinitis usually have similar inflammatory changes in the linings of the paranasal sinuses. (See <a class="local">'Involvement of the paranasal sinuses'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81:478.</a></li><li><a class="nounderline abstract_t">Ng ML, Warlow RS, Chrishanthan N, et al. Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (I). Clin Exp Allergy 2000; 30:1314.</a></li><li><a class="nounderline abstract_t">Ng ML, Warlow RS, Chrishanthan N, et al. Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (II). Clin Exp Allergy 2000; 30:1417.</a></li><li><a class="nounderline abstract_t">Dykewicz MS, Wallace DV, Amrol DJ, et al. Rhinitis 2020: A practice parameter update. J Allergy Clin Immunol 2020; 146:721.</a></li><li><a class="nounderline abstract_t">Borish L. Allergic rhinitis: systemic inflammation and implications for management. J Allergy Clin Immunol 2003; 112:1021.</a></li><li><a class="nounderline abstract_t">Braunstahl GJ. The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease. J Allergy Clin Immunol 2005; 115:142.</a></li><li><a class="nounderline abstract_t">Christodoulopoulos P, Cameron L, Durham S, Hamid Q. Molecular pathology of allergic disease. II: Upper airway disease. J Allergy Clin Immunol 2000; 105:211.</a></li><li class="breakAll">Dunagan DP, Georgitis JW. Intranasal disease and provocation. In: Diagnostic testing of allergic disease, Kemp SF, Lockey RF (Eds), Marcel Dekker, 151 2000.</li><li><a class="nounderline abstract_t">Eifan AO, Durham SR. Pathogenesis of rhinitis. Clin Exp Allergy 2016; 46:1139.</a></li><li><a class="nounderline abstract_t">Worm M, Henz BM. Molecular regulation of human IgE synthesis. J Mol Med (Berl) 1997; 75:440.</a></li><li><a class="nounderline abstract_t">Oettgen HC, Geha RS. IgE in asthma and atopy: cellular and molecular connections. J Clin Invest 1999; 104:829.</a></li><li><a class="nounderline abstract_t">Walls AF, He S, Buckley MG, McEuen AR. Roles of the mast cell and basophil in asthma. Clin Exp Allergy Rev 2001; 1:68.</a></li><li><a class="nounderline abstract_t">Haberal I, Corey JP. The role of leukotrienes in nasal allergy. Otolaryngol Head Neck Surg 2003; 129:274.</a></li><li><a class="nounderline abstract_t">Iwasaki M, Saito K, Takemura M, et al. TNF-alpha contributes to the development of allergic rhinitis in mice. J Allergy Clin Immunol 2003; 112:134.</a></li><li><a class="nounderline abstract_t">Cates EC, Gajewska BU, Goncharova S, et al. Effect of GM-CSF on immune, inflammatory, and clinical responses to ragweed in a novel mouse model of mucosal sensitization. J Allergy Clin Immunol 2003; 111:1076.</a></li><li><a class="nounderline abstract_t">Salib RJ, Kumar S, Wilson SJ, Howarth PH. Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis. J Allergy Clin Immunol 2004; 114:799.</a></li><li class="breakAll">Orban NT, Saleh H, Durham SR. Allergic and non-allergic rhinitis. In: Middleton's allergy: Principles and practice, 7th ed, Adkinson NF, Bochner BS, Busse WW, et al (Eds), Mosby, St. Louis 2009. p.973.</li><li><a class="nounderline abstract_t">Ponikau JU, Sherris DA, Kephart GM, et al. Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis. J Allergy Clin Immunol 2005; 116:362.</a></li><li><a class="nounderline abstract_t">Hanazawa T, Antuni JD, Kharitonov SA, Barnes PJ. Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis. J Allergy Clin Immunol 2000; 105:58.</a></li><li><a class="nounderline abstract_t">Arnal JF, Didier A, Rami J, et al. Nasal nitric oxide is increased in allergic rhinitis. Clin Exp Allergy 1997; 27:358.</a></li><li class="breakAll">Baroody FM, Naclerio RM. Allergic rhinitis. In: Clinical immunology. Principles and practice, 2nd ed, Rich RR, Fleisher TA, Shearer WT, et al (Eds), Mosby, London 2001. p.481.</li><li><a class="nounderline abstract_t">Hansen I, Klimek L, Mösges R, Hörmann K. Mediators of inflammation in the early and the late phase of allergic rhinitis. Curr Opin Allergy Clin Immunol 2004; 4:159.</a></li><li><a class="nounderline abstract_t">Baroody FM, Ford S, Proud D, et al. Relationship between histamine and physiological changes during the early response to nasal antigen provocation. J Appl Physiol (1985) 1999; 86:659.</a></li><li><a class="nounderline abstract_t">Naclerio RM, Proud D, Togias AG, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 1985; 313:65.</a></li><li><a class="nounderline abstract_t">Broide DH, Paine MM, Firestein GS. Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics. J Clin Invest 1992; 90:1414.</a></li><li><a class="nounderline abstract_t">Banov C, LaForce C, Lieberman P. Double blind trial of Astelin nasal spray in the treatment of vasomotor rhinitis. Ann Allergy Asthma Immunol 2000; 84:138.</a></li><li class="breakAll">Abbas AK, Lichtman AH, Pillai S. Allergy. In: Cellular and molecular immunology, 9th edition, Elsevier, New York 2017. p.437.</li></ol></div><div id="topicVersionRevision">Topic 7530 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9860027" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10971479" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (I).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10998018" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Preliminary criteria for the definition of allergic rhinitis: a systematic evaluation of clinical parameters in a disease cohort (II)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32707227" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Rhinitis 2020: A practice parameter update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14657851" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Allergic rhinitis: systemic inflammation and implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15637561" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : The unified immune system: respiratory tract-nasobronchial interaction mechanisms in allergic airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669839" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Molecular pathology of allergic disease. II: Upper airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10669839" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Molecular pathology of allergic disease. II: Upper airway disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27434218" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Pathogenesis of rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9231884" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Molecular regulation of human IgE synthesis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10510320" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : IgE in asthma and atopy: cellular and molecular connections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Roles of the mast cell and basophil in asthma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12958580" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : The role of leukotrienes in nasal allergy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12847490" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : TNF-alpha contributes to the development of allergic rhinitis in mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12743573" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of GM-CSF on immune, inflammatory, and clinical responses to ragweed in a novel mouse model of mucosal sensitization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480318" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15480318" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Nasal mucosal immunoexpression of the mast cell chemoattractants TGF-beta, eotaxin, and stem cell factor and their receptors in allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16083791" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Striking deposition of toxic eosinophil major basic protein in mucus: implications for chronic rhinosinusitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10629453" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Intranasal administration of eotaxin increases nasal eosinophils and nitric oxide in patients with allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146927" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Nasal nitric oxide is increased in allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9146927" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nasal nitric oxide is increased in allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15126935" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Mediators of inflammation in the early and the late phase of allergic rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9931205" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Relationship between histamine and physiological changes during the early response to nasal antigen provocation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2582257" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Inflammatory mediators in late antigen-induced rhinitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1401075" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Eosinophils express interleukin 5 and granulocyte macrophage-colony-stimulating factor mRNA at sites of allergic inflammation in asthmatics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Double blind trial of Astelin nasal spray in the treatment of vasomotor rhinitis</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
